MXPA05007792A - Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas. - Google Patents

Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.

Info

Publication number
MXPA05007792A
MXPA05007792A MXPA05007792A MXPA05007792A MXPA05007792A MX PA05007792 A MXPA05007792 A MX PA05007792A MX PA05007792 A MXPA05007792 A MX PA05007792A MX PA05007792 A MXPA05007792 A MX PA05007792A MX PA05007792 A MXPA05007792 A MX PA05007792A
Authority
MX
Mexico
Prior art keywords
propofol
compositions
amino acid
acid derived
prodrugs
Prior art date
Application number
MXPA05007792A
Other languages
English (en)
Inventor
Thomas W Woiwode
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of MXPA05007792A publication Critical patent/MXPA05007792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02—Monothiocarbonic acids; Derivatives thereof
    • C07C329/04—Esters of monothiocarbonic acids
    • C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion proporciona prodrogas de propofol, metodos para hacer prodrogas de propofol, composiciones farmaceuticas de prodrogas de propofol y metodos para usar prodrogas de propofol y sus composiciones farmaceuticas para tratar o prevenir enfermedades o trastornos como migrana, dolor de cabeza y nausea y vomito despues de una quimioterapia o una intervencion quirurgica.
MXPA05007792A 2003-01-28 2004-01-28 Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas. MXPA05007792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44331503P 2003-01-28 2003-01-28
PCT/US2004/002537 WO2005021024A1 (en) 2003-01-28 2004-01-28 Amino acid derived prodrugs of propofol, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05007792A true MXPA05007792A (es) 2006-01-31

Family

ID=34272366

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007792A MXPA05007792A (es) 2003-01-28 2004-01-28 Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.

Country Status (11)

Country Link
US (1) US7220875B2 (es)
EP (1) EP1587527A4 (es)
JP (1) JP2007521250A (es)
KR (1) KR20060055438A (es)
CN (2) CN101255123A (es)
CA (1) CA2510677A1 (es)
MX (1) MXPA05007792A (es)
NO (1) NO20053972L (es)
NZ (1) NZ540699A (es)
WO (1) WO2005021024A1 (es)
ZA (1) ZA200504940B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543166A1 (en) * 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
JP2008505979A (ja) * 2004-07-12 2008-02-28 ゼノポート，インコーポレイティド プロポフォールのアミノ酸誘導体プロドラッグ、組成物、及びその使用方法
US7241807B2 (en) * 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
ES2340189T3 (es) * 2004-12-23 2010-05-31 Xenoport, Inc. Profarmacos de propofol derivados del aminoacido serina, composiciones, usos y formas cristalinas de los mismos.
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
RU2470908C2 (ru) 2007-05-09 2012-12-27 Сигничер Терапьютикс, Инк. Терапевтические соединения
BRPI0811284A2 (pt) 2007-05-09 2015-01-20 Pharmacofore Inc Compostos terapêuticos
WO2008157627A1 (en) * 2007-06-21 2008-12-24 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
WO2009036322A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of propofol prodrugs for treating neuropathic pain
WO2009092073A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
CN101298426B (zh) * 2008-06-17 2012-08-22 靳广毅 2,6-二异丙基苯酚的水溶性衍生物及其应用
US20100286186A1 (en) * 2009-04-02 2010-11-11 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
WO2011050095A2 (en) * 2009-10-20 2011-04-28 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction (pocd)
CN101906039B (zh) * 2010-06-23 2013-05-08 四川大学华西医院 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用
FR2976944A1 (fr) * 2011-06-21 2012-12-28 Centre Nat Rech Scient Prodrogues peptidiques
CN102381972B (zh) * 2011-09-08 2013-10-30 四川大学华西医院 带有酯结构末端的丙泊酚羟基酸酯类化合物及其制备方法和应用
CN102617380B (zh) * 2012-03-12 2014-04-02 成都一平医药科技发展有限公司 氨基酸与丙泊酚的碳酸二酯水溶性衍生物及其用途
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
CN106132922B (zh) * 2014-02-17 2018-12-04 江苏恩华络康药物研发有限公司 一类水溶性丙泊酚衍生物及其用途
CN108558685B (zh) * 2017-06-08 2020-11-20 西安力邦制药有限公司 2,6-二取代苯酚葡甲胺类衍生物及应用
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
CN111920789A (zh) * 2020-08-17 2020-11-13 中山大学附属第一医院 异丙酚通过促进发育脑多巴胺神经网络形成提高小鼠认知功能的用途
CA3201673A1 (en) * 2020-12-21 2022-06-30 Suoding Cao Drug conjugate, preparation method therefor, and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US4962882A (en) * 1989-11-27 1990-10-16 Sarazen Jr Paul M Ventilator
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IL117474A (en) 1995-03-14 2001-04-30 Siemens Ag Removable precise dosing unit containing inhaled drugs for a hearing aid device
IL117473A (en) 1995-03-14 2001-08-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP1161226B1 (en) 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane

Also Published As

Publication number Publication date
AU2004268492A1 (en) 2005-03-10
NZ540699A (en) 2007-06-29
NO20053972L (no) 2005-08-25
KR20060055438A (ko) 2006-05-23
EP1587527A4 (en) 2009-10-21
CN101255123A (zh) 2008-09-03
AU2004268492B2 (en) 2008-07-31
CA2510677A1 (en) 2005-03-10
EP1587527A1 (en) 2005-10-26
US7220875B2 (en) 2007-05-22
ZA200504940B (en) 2006-09-27
JP2007521250A (ja) 2007-08-02
CN1744908A (zh) 2006-03-08
US20050004381A1 (en) 2005-01-06
WO2005021024A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
PL1781596T3 (pl) Aminokwasowe pochodne prekursory leków związku propofolu i ich zastosowanie
MXPA05007792A (es) Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.
ATE456552T1 (de) Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
DE602006016449D1 (es)
TW200510416A (en) P38 inhibitors and methods of use thereof
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
PL1789398T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
IL182417A0 (en) Mitotic kinesin inhibitors and methods of use thereof
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
WO2005023204A3 (en) Aromatic prodrugs of propofol, compositions and uses thereof
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
WO2003105753A3 (en) METHODS AND COMPOSITIONS FOR GRAFTING FUNCTIONAL LOOPS INTO A PROTEIN

Legal Events

Date Code Title Description
FG Grant or registration